Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database

This report examines relapse risk following a switch from risperidone long-acting injectable (RLAI) to another long-acting injectable antipsychotic [paliperidone palmitate (PP)] versus a switch to oral antipsychotics (APs). Truven Health’s MarketScan Multistate Medicaid Database compared relapses fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Voss, Erica A., Ryan, Patrick B., Stang, Paul E., Hough, David, Alphs, Larry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams And Wilkins 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383368/
https://www.ncbi.nlm.nih.gov/pubmed/25730525
http://dx.doi.org/10.1097/YIC.0000000000000068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383368/
https://www.ncbi.nlm.nih.gov/pubmed/25730525
http://dx.doi.org/10.1097/YIC.0000000000000068

Ejemplares similares